Hims & Hers Health, Inc. (HIMS)
Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?
Hims & Hers benefits from strong product demand and subscriber growth ahead of second-quarter 2025 earnings, fueled by weight loss and specialty care uptake.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Outperforms Broader Market: What You Need to Know
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $58.68, indicating a +1.79% shift from the previous trading day.
HIMS vs. TDOC: Which Direct-to-Consumer Health Stock Wins Now?
Hims & Hers and Teladoc Health are reshaping virtual care, but which has the edge in earnings growth and strategic expansion? Let's see.
Hims & Hers Health, Inc. (HIMS) Reports Next Week: Wall Street Expects Earnings Growth
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hims & Hers Health: What's Wall Street Missing In This Weight-Loss Stock?
Hims & Hers remains a compelling long-term play, with a resilient subscription-driven model, 85%+ retention, and 2.4 million users fueling growth. Despite the Novo Nordisk partnership loss, Hims quickly pivoted, expanding its weight-loss offerings and deepening its holistic digital health platform. Recent financials remained robust with Q1 sales up 111% YOY, recurring revenues, strong cash flow, and rising ARPU, supporting a path to sustained profitability.
Is Hims & Hers the Newest Meme Stock Darling?
Key Points in This Article: Hims & Hers (HIMS) telehealth platform drives strong growth, but the Novo Nordisk partnership fallout and regulatory risks pose challenges.
Here's Why Hims & Hers Health, Inc. (HIMS) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $47.6, signifying a -5.52% move from its prior day's close.
How Hims & Hers Health Is Quietly Changing Healthcare
Hims surpassed 2.4 million subscribers with 95% recurring revenue and over 85% retention, driving 111% YoY revenue growth. Average monthly revenue per subscriber rose 50% YoY, showing strong monetization through personalization, bundling, and chronic care expansion. Despite Novo deal fallout, Hims continues scaling GLP-1 offerings and accelerating proprietary semaglutide development amid regulatory scrutiny.
All You Need to Know About Hims & Hers Health (HIMS) Rating Upgrade to Strong Buy
Hims & Hers Health (HIMS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
